Cystic Fibrosis News Today Weekly Digest

Cystic Fibrosis Weekly Update Contents: AR-501 Named Orphan Drug in EU as Possible Treatment for Chronic Lung Infections in CF Chronic Bullying Is the Worst Sickness of All Vertex Asks FDA to Approve 1st Triple Combo for CF – Elexacaftor, Tezacaftor and Kalydeco AR-501 Named Orphan Drug in EU as Possible Treatment for Chronic Lung Infections in CF Jul 24, 2019 07:00 am | Jose Marques Lopes, PhD The European Medicines Agency (EMA) granted orphan drug status to AR-501, a treatment candidate for lung infections in people with cystic fibrosis (CF). AR-501, developed by Aridis Pharmaceuticals and also known as Panaecin, is an inhaled formulation of gallium citrate intended as a weekly and self-administered therapy delivered directly to the lungs. A non-antibiotic small molecule, […] The post AR-501 Named Orphan Drug in EU as Possible Treatment for Chronic Lung Infections in CF appeared first on Cystic Fibrosis News Today. Read More Chronic Bullying Is the Worst Sickness of All Jul 23, 2019 03:00 pm | Bailey Vincent It sucks being sick. This is a fact. But, contrary to popular belief, being sick doesn’t make you a better person. This is also a fact. I can be the most hyperbolic person ever. I handle criticism on astronomically poor levels. I am so sensitive that I avoid conflict like it’s Pseudomonas. I have a […] The post Chronic Bullying Is the Worst Sickness of All appeared first on Cystic Fibrosis News Today. Read More Vertex Asks FDA to Approve 1st Triple Combo for CF – Elexacaftor, Tezacaftor and Kalydeco Jul 23, 2019 07:00 am | Marisa Wexler MS Vertex Pharmaceuticals is asking the U.S. Food and Drug Administration to approve a first triple combination therapy —  elexacaftor (VX-445) plus tezacaftor, and ivacaftor (Kalydeco) — to treat cystic fibrosis (CF) patients who cannot use its other disease-modifying treatments or don’t benefit as intended. Triple combinations include “next generation” correctors being developed to treat the estimated 40% of […] The post Vertex Asks FDA to Approve 1st Triple Combo for CF – Elexacaftor, Tezacaftor and Kalydeco appeared first on Cystic Fibrosis News Today. Read More   Recent News ‘Everything’ Will Never Be Perfect, and That’s OK Kalydeco’s Safety and Benefits Studied in CF Patients with Severe Lung Disease NIH $150,000 Grant to Support Research into Preserving Fertility in Women Prior to Lung Transplant How Much CF Do You Choose to Show? European Initiative Targets Diagnosis, Treatment of Rare Diseases